Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

J. C. Davis, D. M. Van Der Heijde, J. Braun, M. Dougados, J. Cush, D. Clegg, R. D. Inman, A. Kivitz, L. Zhou, A. Solinger, W. Tsuji

Research output: Contribution to journalArticlepeer-review

149 Scopus citations

Abstract

Objective: To evaluate the continued safety and durability of clinical response in patients with ankylosing spondylitis receiving etanercept. Methods: 277 patients who had participated in a previous randomised, double blind, placebo controlled 24 week trial were eligible to continue in this open label extension study. All patients who enrolled in the open label extension (n = 257) received subcutaneous etanercept 25 mg twice weekly for up to 72 weeks, for a combined 96 weeks of cumulative trial and open label experience. For the patients who had received etanercept for 24 weeks in the double blind trial, this represented almost 2 years of continuous etanercept treatment. Results: Patients continuing etanercept treatment had a sustained response for almost 2 years, with 74% achieving an ASsessments in Ankylosing Spondylitis 20% (ASAS 20) response after 96 weeks of etanercept treatment. Patients who had received placebo in the preceding double blind trial had similar responses, with 70% of patients attaining an ASAS 20 response after 24 weeks of etanercept treatment and 78% achieving an ASAS 20 response after 72 weeks. Improved spinal mobility was seen in both groups. Etanercept was well tolerated in patients treated for up to 96 weeks. Conclusion: The subcutaneous administration of twice weekly doses of etanercept provided sustained durability of response in the improvement of signs and symptoms of ankylosing spondylitis for nearly 2 years.

Original languageEnglish (US)
Pages (from-to)1557-1562
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume64
Issue number11
DOIs
StatePublished - Nov 2005
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks'. Together they form a unique fingerprint.

Cite this